Evaxion A/S (EVAX) Competitors $6.79 -2.81 (-29.27%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$7.16 +0.38 (+5.52%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX vs. ELUT, PYRGF, VRCA, LIMN, NEUP, PLUR, MURA, MAAQ, ITRM, and TENXShould you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Elutia (ELUT), PyroGenesis Canada (PYRGF), Verrica Pharmaceuticals (VRCA), Liminatus Pharma (LIMN), Neuphoria Therapeutics (NEUP), Pluri (PLUR), Mural Oncology (MURA), Mana Capital Acquisition (MAAQ), Iterum Therapeutics (ITRM), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. Evaxion A/S vs. Its Competitors Elutia PyroGenesis Canada Verrica Pharmaceuticals Liminatus Pharma Neuphoria Therapeutics Pluri Mural Oncology Mana Capital Acquisition Iterum Therapeutics Tenax Therapeutics Elutia (NASDAQ:ELUT) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Does the media favor ELUT or EVAX? In the previous week, Evaxion A/S had 5 more articles in the media than Elutia. MarketBeat recorded 9 mentions for Evaxion A/S and 4 mentions for Elutia. Elutia's average media sentiment score of 0.32 beat Evaxion A/S's score of -0.11 indicating that Elutia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ELUT or EVAX more profitable? Evaxion A/S has a net margin of 0.00% compared to Elutia's net margin of -90.01%. Elutia's return on equity of 0.00% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets Elutia-90.01% N/A -54.08% Evaxion A/S N/A -319.52%-63.56% Do analysts recommend ELUT or EVAX? Elutia presently has a consensus target price of $7.00, indicating a potential upside of 685.90%. Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 62.00%. Given Elutia's higher possible upside, equities research analysts clearly believe Elutia is more favorable than Evaxion A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders believe in ELUT or EVAX? 74.0% of Elutia shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, ELUT or EVAX? Evaxion A/S has lower revenue, but higher earnings than Elutia. Evaxion A/S is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElutia$23.68M1.59-$53.95M-$1.06-0.84Evaxion A/S$3.34M2.85-$10.57M-$1.32-5.14 Which has more risk and volatility, ELUT or EVAX? Elutia has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. SummaryElutia beats Evaxion A/S on 9 of the 14 factors compared between the two stocks. Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.52M$2.25B$6.19B$10.55BDividend YieldN/AN/A5.70%4.81%P/E Ratio-5.1439.7185.5427.13Price / Sales2.8517.69610.73132.72Price / CashN/A59.9337.1060.81Price / Book-5.7512.2912.236.52Net Income-$10.57M-$65.79M$3.33B$276.93M7 Day Performance15.08%0.97%1.17%1.93%1 Month Performance119.74%4.06%6.85%2.19%1 Year Performance-48.56%30.24%58.93%34.62% Evaxion A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion A/S1.9017 of 5 stars$6.79-29.3%$11.00+62.0%-50.6%$9.52M$3.34M-5.1460Analyst ForecastShort Interest ↑Gap DownELUTElutia3.1261 of 5 stars$0.89-1.3%$7.00+683.9%-74.7%$37.86M$24.38M-0.84180PYRGFPyroGenesis Canada0.5269 of 5 stars$0.20+5.3%N/A-67.0%$37.59M$9.14M-3.3390News CoverageVRCAVerrica Pharmaceuticals3.6952 of 5 stars$3.97-3.2%$60.00+1,411.3%-74.1%$37.52M$7.57M-0.4840Short Interest ↑LIMNLiminatus PharmaN/A$1.38-2.1%N/AN/A$37.36MN/A0.00N/ANegative NewsShort Interest ↑NEUPNeuphoria Therapeutics2.1251 of 5 stars$15.71-6.0%$28.00+78.2%N/A$37.08M$15.65M0.00N/AGap DownPLURPluri2.4297 of 5 stars$4.50+0.3%$12.00+167.0%-10.6%$36.68M$1.34M-0.87150News CoveragePositive NewsMURAMural Oncology3.3071 of 5 stars$2.09-0.2%$12.00+475.5%-43.3%$36.13MN/A-0.24119MAAQMana Capital AcquisitionN/A$4.44+6.9%N/A+1,927.9%$36.03MN/A0.001ITRMIterum Therapeutics1.9754 of 5 stars$0.74+1.2%$9.00+1,117.9%-42.4%$34.86MN/A-0.8710News CoverageTENXTenax Therapeutics1.857 of 5 stars$7.50+1.1%$18.00+140.2%+69.1%$34.18MN/A-8.159News CoverageAnalyst ForecastShort Interest ↑ Related Companies and Tools Related Companies Elutia Competitors PyroGenesis Canada Competitors Verrica Pharmaceuticals Competitors Liminatus Pharma Competitors Neuphoria Therapeutics Competitors Pluri Competitors Mural Oncology Competitors Mana Capital Acquisition Competitors Iterum Therapeutics Competitors Tenax Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVAX) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.